A5071573183- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Long-Term Effects of COVID-19
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pulmonary Hypertension Research and Treatments
- Eosinophilic Disorders and Syndromes
- Intensive Care Unit Cognitive Disorders
- Inflammatory Myopathies and Dermatomyositis
- COVID-19 and Mental Health
- COVID-19 Clinical Research Studies
- IgG4-Related and Inflammatory Diseases
- Spondyloarthritis Studies and Treatments
- Skin Diseases and Diabetes
- Frailty in Older Adults
- Respiratory and Cough-Related Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Pneumonia and Respiratory Infections
- Medical Imaging and Pathology Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Pediatric health and respiratory diseases
- Urticaria and Related Conditions
- Autoimmune and Inflammatory Disorders
- Medical Imaging Techniques and Applications
University of Leicester
2016-2024
University Hospitals of Leicester NHS Trust
2019-2024
Glenfield Hospital
2015-2023
Imperial College London
2010-2023
Seattle University
2023
University of Manchester
2023
Manchester Academic Health Science Centre
2023
Manchester University NHS Foundation Trust
2023
Queen Mary University of London
2023
National Institute for Health Research
2023
Objectives. The prevalence of interstitial lung disease (ILD) in RA is ∼5%. Previous work identified increasing age, active articular and damage as risk factors for RA-associated ILD (RA-ILD). roles high-resolution CT (HRCT) function testing defining the nature extent pulmonary involvement have recently been explored. This study first to examine predictive prognostic development RA-ILD report on physiological radiological characteristics condition from a large multicentre UK network....
The impact of coronavirus disease (COVID-19) on patients with interstitial lung (ILD) has not been established.
The HLA class II (DRB1 and DQB1) associations with sarcoidosis have been studied by several groups but often without consistent results. In this paper, we consider the hypothesis that observed inconsistencies relate to distinct, genetically encoded disease phenotypes which differ in prevalence between centres. We therefore typed HLA-DRB1 DQB1 340 UK, 139 Dutch 163 Japanese patients and, respectively, 354, 218 168 healthy controls from these populations. applied phenotyping genotyping...
This study explores whether the prognosis of interstitial lung disease in rheumatoid arthritis (RA-ILD) has improved over time and assesses potential influence drug therapy a large multicentre UK network.We analysed data from 18 centres on patients meeting criteria for both RA ILD diagnosed 25-year period. Data included age, duration, outcome cause death. We compared all respiratory mortality between controls RA-ILD patients, assessing specific drugs four quartiles based year diagnosis.A...
To investigate novel systemic sclerosis (SSc) autoantibodies in autoantibody-negative patients and establish clinical associations.Serum samples data for 548 with SSc were collected. Routine serologic techniques used to test the serum known autoantibodies, negative results further investigated by radiolabeled-protein immunoprecipitation assay. Sera that immunoprecipitated a 30-kd band analyzed indirect immunofluorescence immunoprecipitation, using depleted cell extracts common reactivity....
Abstract Rationale The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established. Objectives To assess outcomes following in ILD versus those without a contemporaneous age, sex and comorbidity matched population. Methods An international multicentre audit prior diagnosis admitted to hospital between 1 March May 2020 was undertaken compared patients, obtained from the ISARIC 4C cohort, over same period. primary outcome survival. Secondary analysis...
The factors determining disease course and survival in fibrotic hypersensitivity pneumonitis (fHP) have not been fully elucidated.The aim of this study was to describe the characteristics patients with fHP a real-world cohort investigate associated worse outcomes. We aimed explore use neutrophil lymphocyte ratio (NLR) peripheral blood monocyte levels predicting mortality.
<h3>Background</h3> There is little evidence base to guide clinicians in the management of patients with rheumatoid arthritis (RA) related interstitial lung disease (ILD). In subgroup who have rapidly deteriorating respiratory function, pulsed cyclophosphamide has been advocated but no assessment its efficacy published. The British Rheumatoid InterstitiaL Lung (BRILL) network collected data on treatment and outcomes 260 RA-ILD, which allow this therapeutic strategy. <h3>Objectives</h3> To...
ABSTRACT Background Interstitial lung disease (ILD) is a known complication of rheumatoid arthritis (RA) with lifetime risk in any individual 7.7%. The TRAIL1 trial was randomized, double-blinded, placebo-controlled, phase 2 study safety, tolerability, and efficacy pirfenidone for the treatment patients RA-ILD. Methods intended to enroll 270 adult (18 85 years) established RA-ILD at 33 sites 4 countries. Patients were randomly assigned (1:1) 2,403 mg oral or placebo daily. primary endpoint...
<h3>Background</h3> Clinically relevant interstitial lung disease (ILD) is present in approximately 5% of patients with rheumatoid arthritis (RA). Traditionally, oral steroids have been used to treat this manifestation RA, but no evidence base exists support this. Indeed, concern has raised that such an approach might be associated increased mortality ILD [1]. <h3>Objectives</h3> We examined the effect steroid therapy on a large multi centre group retrospectively assess these agents...
<b>Introduction:</b> Oral anti-fibrotics attenuate lung function decline in IPF however side effects are common, and often result discontinuation or dose reduction. Nebulised pirfenidone achieves a 35-fold higher peak epithelial lining fluid concentration 1/15th of the systemic exposure than standard oral pirfenidone, with less frequent stabilisation FVC phase Ib study (West A, et al. Thorax 2023, accepted for publication). <b>Methods:</b> A II open-label extension nebulised progressive...